Cyclopharm (ASX:CYC) received an additional installation purchase order from a US Department of Veterans Affairs hospital for its Technegas product after its deployment under the Federal Supply
Schedule, according to a Tuesday Australian bourse filing.
Technegas is a structured ultra-fine dispersion of radioactive labelled carbon, which allows for views and tomography imaging under a gamma or single photon emission computed tomography camera.
Its sales receipts in the US exceeded $1 million since commercial sales began last year. Its US installed base as of March 31 reached 27 technegas systems, from 17 systems as of Dec. 31, 2024.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。